Table 3.
Antitumoral treatment outcomes following immune checkpoint inhibitor-induced cytokine release syndrome.
Antitumoral treatment outcome | value (n = 22)* |
---|---|
CR | 1 (4,5%) |
PD | 15 (68%) |
SD | 1 (4,5%) |
PR | 5 (23%) |
Median duration of response on ICI | 12 months |
CR = Complete response, PR = Partial response, SD= Stable disease, PD = Progressive disease, ICI = immune checkpoint inhibitor.
*22 patients had evaluable radiological assessment following CRS.